---
title: Validation Plan for R&D AI Pilot
doc_type: validation plan
owner: R&D Quality / AI Governance
status: draft
company: ACME Pharma
confidentiality: Internal
scenario: AI in Research and Development planning evidence
Document_File_Name: 12_validation_plan.md
IIA_Type: GOV
IIA_Type_Rational: The document is a validation plan that defines the governance framework
  for testing the AI pilot's compliance with requirements before expansion, making
  it a governance document.
Quality_Rating: M
Relevance_Score: H
Fact: 'The validation plan defines test categories including retrieval relevance,
  context handling, citation quality, limitation recognition, safety boundaries, and
  reviewer usability. Acceptance criteria must exist before expansion beyond the sandbox.
  The plan identifies residual risk of overreliance if users treat confident wording
  as scientific evidence. It uses a risk-based assurance approach: for exploratory
  literature support, evidence focuses on intended use, user training, source traceability,
  and output review; for GxP or submission-support workflows, a stronger package is
  required including requirements, risk assessment, test cases, traceability matrix,
  audit trail review, access-control evidence, change-control procedure, and periodic
  review. The plan aligns with FDA''s risk-based computer software assurance, Part
  11, and GAMP 5. Test scenarios include blocking restricted internal research notes
  from unapproved external processing, requiring scientist approval for experiment-design
  suggestions, preventing lab-note synthesis from overwriting original records, and
  handling retrieval misses with contradictory evidence. The assurance approach is
  risk-based, not uniform for every AI use case.'
Summary: 'The document is a validation plan for ACME Pharma''s R&D AI pilot. The validation
  objective is to test whether the AI workflow produces useful, traceable, and reviewable
  suggestions under controlled conditions, not to prove scientific correctness. Six
  test categories are defined: retrieval relevance, context handling, citation quality,
  limitation recognition, safety boundaries, and reviewer usability. Acceptance criteria
  must be established before expansion beyond the sandbox, though specific thresholds
  are not provided. The plan acknowledges residual risk of overreliance if users treat
  confident AI output as scientific evidence. A risk-based assurance model is adopted:
  for exploratory literature support, evidence focuses on intended use, user training,
  source traceability, and output review; for workflows that may affect GxP or submission-support
  records, a more rigorous package is required, including requirements, risk assessment,
  test cases, traceability matrix, audit trail review, access-control evidence, change-control
  procedure, and periodic review. The plan aligns with FDA''s risk-based computer
  software assurance, Part 11 principles, and GAMP 5 themes. Seven test scenarios
  are described, such as blocking restricted internal notes from unapproved external
  processing, requiring scientist approval for experiment-design suggestions, and
  preventing lab-note synthesis from overwriting original records. The assurance approach
  is risk-based and not uniform for every AI use case.'
Section_Context: Governance framework
IIA_Relevance_Explanation: The document is a validation plan that defines the governance
  framework for testing the AI pilot's compliance with requirements before expansion,
  making it a governance document.
IIA_Relevance: H
IIA_Confidence: M
Notes: 'Auto-derived categorization: The document is a validation plan that defines
  the governance framework for testing the AI pilot''s compliance with requirements
  before expansion, making it a...'
---

# Validation Plan for R&D AI Pilot


## Validation objective

The pilot validation does not prove scientific correctness. It tests whether the workflow produces useful, traceable, and reviewable suggestions under controlled conditions.

## Test categories

- Retrieval relevance: does the system find the right documents and passages?
- Context handling: does it consider broader source context rather than isolated snippets?
- Citation quality: are references specific and reviewable?
- Limitation recognition: does it state uncertainty and missing evidence?
- Safety boundaries: does it refuse or flag requests that involve restricted data or unapproved use?
- Reviewer usability: can scientists identify what was used and why?

## Acceptance criteria

Acceptance criteria are qualitative and quantitative but are not listed here as thresholds. The important planning point is that acceptance criteria must exist before expansion beyond the sandbox.

## Residual risk

Even a validated pilot may create overreliance risk if users treat confident wording as scientific evidence.

## Validation and assurance approach

The validation plan uses a risk-based assurance model. For exploratory literature support, evidence focuses on intended use, user training, source traceability, and output review. For workflows that may affect GxP or submission-support records, the plan requires a stronger package: requirements, risk assessment, test cases, traceability matrix, audit trail review, access-control evidence, change-control procedure, and periodic review.

## Reference expectations considered

The plan aligns with three public expectation families: FDA's risk-based computer software assurance direction for production and quality-system software, FDA Part 11 principles for electronic records and signatures where predicate records are involved, and GAMP 5's fit-for-intended-use, supplier involvement, critical thinking, data-integrity, cloud, and AI/ML lifecycle themes.

## Test scenarios

1. Public literature-only summary with correct source citations.
2. Restricted internal research note blocked from unapproved external processing.
3. Experiment-design suggestion requiring scientist approval before use.
4. Lab-note synthesis request that must not overwrite the original record.
5. Retrieval miss where contradictory evidence exists in a different source.
6. Supplier support access to a failed job containing restricted content.
7. Changed model or retrieval configuration requiring regression testing.

## Assurance approach

The validation plan uses a risk-based assurance approach rather than one uniform validation package for every AI use case. Productivity support using public information requires documented intended use, user guidance, and basic output review. Internal research data use requires security, privacy, legal/IP, data-flow, access, and output-review evidence. GxP-adjacent or submission-support use requires a stronger fit-for-intended-use rationale, traceability, change control, audit trail expectations, and review of how outputs enter controlled records.

The plan defines test categories: source retrieval accuracy, output grounding, contradiction handling, uncertainty labeling, human-review workflow, access control, logging, retention, deletion, and model-change impact. It also requires negative tests, such as asking the assistant to produce unsupported conclusions, use restricted data in an unapproved workspace, or treat draft output as final evidence.

## Evidence package

The expected evidence package includes intended-use statement, risk classification, data-flow record, test scripts or evaluation examples, reviewer scoring, defect log, release approval, monitoring plan, training record, and change-control procedure. For supplier co-development, the package must also include contract clauses, support-access rules, subprocessor evidence, no-training commitments, and exit/deletion requirements.

The audit should determine whether the plan is actually executed. A validation plan with no completed test evidence is not sufficient for routine use, especially where output could influence candidate prioritization, regulatory drafting, or research records.

## Detailed audit scenario and sample evidence

For audit planning, this artifact would normally be supported by several underlying records rather than read in isolation. Expected supporting evidence includes the accountable owner, approval date, related use-case ID, related system ID, affected R&D functions, data classes permitted, supplier involvement, intended decision impact, and the operating procedure or workflow that tells users what to do. A mature record would also show exceptions, issue follow-up, and the date when the artifact was last challenged by governance.

A realistic sample for 12 validation plan would include at least one discovery-science workspace, one translational-science workspace, and one regulatory-science or quality-adjacent scenario. The sample should show whether the same rule is applied differently depending on data class. Public literature summaries should have lighter evidence requirements. Restricted research content should require project-owner approval, traceability to source material, and explicit output-review responsibility. GxP-adjacent or submission-support use should require a documented boundary assessment and stronger change-control evidence.

The most useful audit evidence is not the existence of the document itself. It is the join between this document and operating records: inventory entries, project approvals, access groups, supplier clauses, monitoring logs, training completion, and examples of outputs reviewed or rejected. If those joins cannot be shown, the control may exist on paper but not operate reliably.

## Questions for walkthroughs

During walkthroughs, the audit team should ask who owns this artifact, how teams know when it applies, what happens when a pilot changes scope, where exceptions are logged, and how management knows the artifact is being followed. The team should also ask for one example where the rule stopped or changed a proposed AI use. Evidence of a controlled rejection, redesign, or escalation is often a stronger sign of governance maturity than a list of approved pilots.